Abstract

EDITOR, - Simon Voss and Fiona Harris's concerns about postmarketing surveillance need to be challenged.1 Without producing any evidence the authors imply deceit by pharmaceutical companies in three ways: firstly, by using “so called” independent research companies that do not acknowledge their link with the pharmaceutical companies; secondly, by using postmarketing surveillance to promote their products; and, thirdly, by effectively paying general practitioners to prescribe particular drugs. The implication, which the evidence clearly refutes, is that postmarketing surveillance is not carried out to acceptable moral, professional, or scientific standards. We undertake major postmarketing surveillance studies and clearly acknowledge the sponsor when recruiting doctors. These studies are conducted according to all applicable regulations and guidelines, and include review of data; double entry of data; and audit of selected sites, data handling, and statistical procedures. Such rigorous standards, which are not adhered to in most academic research, makes postmarketing surveillance expensive. Postmarketing surveillance is …

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.